GlassScriptPhysician profile
Cameron Dennis
NPI 1922756196
$7,279.83
in general payments reported to CMS, 2019-2025
50 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.24 · 2022: $1,399 · 2023: $1,775 · 2024: $2,174 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,740 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,740.09 |
| Education | $113.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $635.74 | 2022-2025 | |
| Incyte Corporation | $522.70 | 2022-2025 | Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $506.90 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $474.63 | 2021-2025 | |
| Daiichi Sankyo INC. | $464.83 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $436.23 | 2023-2025 | Tecvayli, Darzalex, Rybrevant |
| Astellas Pharma US INC | $362.49 | 2023-2025 | Vyloy, Xtandi, Xospata |
| Astrazeneca Pharmaceuticals LP | $251.73 | 2022-2025 | Enhertu |
| Celgene Corporation | $233.15 | 2023-2025 | Reblozyl |
| Genzyme Corporation | $224.56 | 2023-2024 | |
| Pfizer INC. | $193.17 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $172.52 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| G1 Therapeutics, INC. | $170.37 | 2022-2023 | Cosela |
| Eisai INC. | $170.00 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $159.78 | 2022-2025 | Opdivo, Opdualag |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $159.19 | 2022-2025 | Vpriv, Fruzaqla, Iclusig |
| Exelixis INC. | $157.70 | 2024-2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $125.67 | 2022-2025 | Xpovio |
| Gilead Sciences, INC. | $120.02 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $114.52 | 2023-2025 | Libtayo |
| Coherus Oncology, INC. | $114.18 | 2022-2024 | |
| Tersera Therapeutics LLC | $103.80 | 2022-2023 | Zoladex |
| Adaptive Biotechnologies Corporation | $101.43 | 2024-2025 | Clonoseq |
| Taiho Oncology, INC. | $101.25 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $99.66 | 2024-2025 | Monoferric, Cosela |
| Glaxosmithkline, LLC. | $85.06 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Beigene USA, INC. | $77.73 | 2022-2024 | Brukinsa |
| Kite Pharma, INC. | $74.95 | 2024-2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $72.27 | 2022-2023 | Qinlock |
| Stemline Therapeutics INC. | $69.15 | 2023-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $64.50 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $58.03 | 2025 | Polivy, Tecentriq |
| Lilly USA, LLC | $56.94 | 2023-2025 | Jaypirca, Verzenio |
| Array Biopharma INC | $55.51 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Amgen INC. | $50.20 | 2022 | |
| Seagen INC. | $44.86 | 2022-2023 | Adcetris |
| Janssen Pharmaceuticals, INC | $44.42 | 2022-2023 | Xarelto |
| Myriad Genetic Laboratories, INC. | $44.05 | 2023-2025 | Precisetumor, Myrisk |
| Octapharma USA, INC. | $43.31 | 2023 | Panzyga |
| Progenics Pharmaceuticals, INC. | $37.89 | 2022-2023 | Pylarify |
| Pharmaessentia USA Corporation | $36.69 | 2025 | Besremi |
| Sobi, INC | $33.50 | 2022-2023 | |
| Emd Serono, INC. | $30.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.58 | 2025 | |
| Sanofi US Services INC. | $18.41 | 2025 | |
| Epizyme, INC. | $17.12 | 2022 | |
| Dendreon Pharmaceuticals LLC | $16.71 | 2025 | Provenge |
| Beone Medicines USA, INC. | $14.84 | 2025 | Brukinsa |
| Caris Mpi, INC. | $14.02 | 2025 | Mi Cancer Seek |
| Global Blood Therapeutics, INC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Dennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.